Your browser doesn't support javascript.
loading
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Kunos, Charles; Deng, Wei; Dawson, Dawn; Lea, Jayanthi S; Zanotti, Kristine M; Gray, Heidi J; Bender, David P; Guaglianone, Perry P; Carter, Jori S; Moore, Kathleen N.
Afiliação
  • Kunos C; *Summa Cancer Institute, Summa Health System, Akron, OH; †NRG Oncology/Gynecologic Oncology Group Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY; ‡Case Western Reserve University, Cleveland, OH; §UT Southwestern Medical Center, Dallas, TX; ∥University Hospitals Case Medical Center, Cleveland, OH; ¶University of Washington, Seattle, WA; #University of Iowa, Iowa City, IA; **Decatur Memorial Hospital, Cancer Care Specialists of Central Illinois, Decatur, IL; ††Vi
Int J Gynecol Cancer ; 25(3): 484-92, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25594147

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias do Colo do Útero / Recidiva Local de Neoplasia Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias do Colo do Útero / Recidiva Local de Neoplasia Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article